Evidence map›Paper›PMID 40851107›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025

MicroRNA-153-3p targets repressor element 1-silencing transcription factor (REST) and neuronal differentiation: Implications for Alzheimer's disease.

Ruizhi Wang, Bryan Maloney, John S Beck, Scott E Counts, Debomoy K Lahiri

Abstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ruizhi WangDepartment of Psychiatry, Laboratory of Molecular Neurogenetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.ORCID 0009-0008-8215-3524
Bryan MaloneyDepartment of Psychiatry, Laboratory of Molecular Neurogenetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.ORCID 0000-0003-2364-9649
John S BeckDepartment of Translational Neuroscience, Michigan State University College of Human Medicine, Grand Rapids, Michigan, USA.
Scott E CountsDepartment of Translational Neuroscience, Michigan State University College of Human Medicine, Grand Rapids, Michigan, USA.ORCID 0000-0003-2851-9763
Debomoy K LahiriDepartment of Psychiatry, Laboratory of Molecular Neurogenetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.ORCID 0000-0002-1664-5933

Funding

Tumor Microenvironment and Metastasis ProgramP30CA082709 · NCI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI David W Clapp · 1999 to 2026
$59.3M
TAU, AB, SYNUCLEIN AND NITRATIVE/OXIDATIVE DAMAGE IN MCIP01AG014449 · NIA · UNIVERSITY OF PITTSBURGH · PI MUFSON, ELLIOTT JAY · 1997 to 2024
$39.7M
Quality Assurance and Quality Control Project Management: Improving Submissions and Study Conduct in the Human Subjects Research Prior Approval ProcessUL1TR002529 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI MOE, SHARON M, WIEHE, SARAH ELIZABETH · 2018 to 2022
$27.2M
Research Education ComponentP30AG072976 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI ANDREW J SAYKIN · 2021 to 2026
$24.1M
Role of microRNA in regulating Fe, Amyloid, and Tau (FeAT) in Alzheimer's diseaseR56AG072810 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI LAHIRI, DEBOMOY K · 2021 to 2021
$630k
Neurobiological Role of MicroRNA in Alzheimer'sR56AG051086 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI LAHIRI, DEBOMOY K · 2023 to 2023
$627k
Testing a Novel Approach to Solve the On-target, Off-site Effects of Alzheimer's DrugsR21AG056007 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI LAHIRI, DEBOMOY K · 2019 to 2020
$435k
Alzheimer's disease-linked microRNA Exploration of UTR Polymorphisms (AdmiRE-UP)R21AG074539 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI LAHIRI, DEBOMOY K · 2022 to 2022
$435k
Indiana Alzheimer's Disease Research Center NIA-P30 AG072976Michigan Alzheimer's Disease Research Center NIA-P30 AG072931NIA/NIH 1R21 AG076202NIA/NIH 2R56 AG051086NIA NIH HHS P01 AG014449NIA NIH HHS P30 AG072976NIA NIH HHS R21 AG056007NIA NIH HHS R21 AG074539NIA NIH HHS R56 AG051086NIA NIH HHS R56 AG072810NIH HHS P30CA082709NIH HHS UL1TR002529
6 · The paper itself

Abstract

introductionSmall non-coding microRNAs (miRNAs) play essential roles in Alzheimer's disease (AD) pathogenesis. Repressor element 1-silencing transcription factor (REST) is involved in AD, though its regulation remains unclear.

methodsWe performed real-time quantitative polymerase chain reaction (qPCR) in autopsied brain tissues to determine miR-153-3p and AD associations. A reporter-based assay measured the activity of REST mRNA 3'-untranslated region (3'-UTR). Induced pluripotent stem cells (iPSC)-derived neurons and human cell lines were applied to determine miR-153-3p regulation of endogenous proteins.

resultsElevation of miR-153-3p is associated with a reduced probability of AD, while elevated REST is associated with a greater probability of AD. The 3'-UTR functional assay pinpointed the miR-153-3p binding sites. miR-153-3p treatment reduced REST, amyloid precursor protein (APP), and α-synuclein (SNCA) 3'-UTR activities and protein levels. miR-153-3p treatment altered REST and neuronal differentiation in iPSC-derived neuronal stem cells. RNA-sequencing and proteomics revealed miR-153-3p-associated networks. DISCUSSION: miR-153-3p reduces REST, APP, and SNCA expression, pointing toward its therapeutic and biomarker potential in neurodegenerative diseases. HIGHLIGHTS: With the increased emphasis on comorbidities of Alzheimer's disease (AD) and other neurodegenerative diseases, we identified that miR-153-3p, as a master regulator, reduced a group of neurodegeneration related proteins: REST, amyloid precursor protein (APP) and α-synuclein (SNCA) levels. The elevation of miR-153-3p levels is associated with reduced probability of AD in posterior cingulate cortex (PCC), while REST, by contrast, is associated with a greater probability of AD. miR-153-3p treatment alters REST protein levels and neuronal differentiation in induced pluripotent stem cells (iPSC) derived neuronal cells. RNA sequencing proteomics and interactome analysis revealed the role of miR-153-3p in axonal guidance.

Indexed as

3' Untranslated RegionsAlzheimer DiseaseMicroRNAsRepressor Proteinsalpha-SynucleinAmyloid beta-Protein PrecursorBinding SitesCell DifferentiationCell LineCognitive DysfunctionHumansInduced Pluripotent Stem CellsNeuronsRE1-Silencing Transcription Factor3' Untranslated Regionsalpha-SynucleinAmyloid beta-Protein PrecursorMicroRNAsMIRN153 microRNA, humanRE1-Silencing Transcription FactorRepressor ProteinsSNCA protein, humanamyloidbiomarkerdementiadrug targetnon‐codingRESTUTR activity

Identifiers

PMID40851107
PMCPMC12375434

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.